文献速递神经肿瘤

胶质母细胞瘤患者的肿瘤性脑膜病:36例分析

Meningeosis Neoplastica in Patients with Glioblastoma: Analysis of 36 Cases.
PubMed 文献 · World Neurosurg · 2022-11-01

这项双中心病例系列纳入2009至2021年德国哥廷根大学医学中心及2012至2018年俄罗斯Burdenko神经外科研究所因WHO IV级原发性和继发性胶质母细胞瘤(GBM)手术的患者,分析肿瘤性脑膜病的临床病程与结局。36例患者中位总生存11个月、无进展生存8个月,肿瘤性脑膜病在初诊后中位2个月出现,出现至死亡中位3个月;挽救治疗未改善该队列结局。

要点

  • 肿瘤性脑膜病在36例GBM患者中表现为脊髓转移9例、室管膜播散12例、软脑膜播散15例。
  • 初诊时中位年龄56岁,常见症状为头痛、恶心、呕吐和急性截瘫。
  • 肿瘤性脑膜病出现后中位生存仅3个月,挽救治疗未改善该队列结局。

核心结论

  • 肿瘤性脑膜病是GBM的罕见表现,预后差,出现后总生存仅略长于3个月,本队列中挽救治疗未改善结局。

研究设计与样本

  • 双中心病例系列,纳入2009至2021年德国哥廷根大学医学中心及2012至2018年俄罗斯Burdenko神经外科研究所因WHO IV级原发性和继发性GBM手术的患者。
  • 纳入标准为病程不同时间点出现GBM软脑膜、室管膜或脊髓播散的临床和神经影像学征象。

主要发现

  • 36例患者中,脊髓转移9例,室管膜播散12例,软脑膜播散15例。
  • 初诊原发性肿瘤时中位年龄56岁,典型症状为头痛、恶心、呕吐和急性截瘫。
  • 中位总生存11个月,中位无进展生存8个月。
  • 肿瘤性脑膜病在初始肿瘤诊断后中位2个月出现,出现至死亡的中位时间为3个月。

关键数值与推荐

  • 挽救治疗包括脑室腹腔分流、脊髓转移灶减压和脊柱放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Meningeosis neoplastica is a rare manifestation of high-grade gliomas and is usually associated with a devastating outcome. The aim of this bicenter series was to investigate the clinical course and outcome of patients with meningiosis neoplastica. METHODS: This case series included patients in whom surgery was performed for World Health Organization grade IV primary and secondary glioblastoma (GBM) at the University Medical Center Göttingen, Göttingen, Germany between 2009 and 2021 and Burdenko Institute of Neurosurgery, Moscow, Russia between 2012 and 2018. Inclusion criteria were manifestation of clinical and neuroradiologic signs of leptomeningeal, ependymal, or spinal dissemination of GBM at various time points during the course of the disease. RESULTS: Meningeosis neoplastica was found in 36 patients. Nine patients developed spinal metastases and 12 ependymal dissemination and 15 patients had a leptomeningeal manifestation of high-grade glioma. The median age of patients at first diagnosis of primary tumor was 56 years. Typical symptoms were headache, nausea, vomiting, and acute paraplegia. The median overall survival was 11 months and progression-free survival was 8 months. Meningeosis neoplastica developed a median 2 months after the initial tumor diagnosis. Salvage therapies included ventriculoperitoneal shunting, decompression of spinal metastases, and spinal radiation therapy. The median time between meningeosis manifestation and death was 3 months. CONCLUSIONS: Meningeosis neoplastica is a rare manifestation of GBM. It has a poor prognosis. The overall survival after the manifestation of meningeosis was barely longer than 3 months. Salvage therapies did not improve the outcome in our patient cohort.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Sachkova A, Khadhraoui E, Goryaynov S, et al. Meningeosis Neoplastica in Patients with Glioblastoma: Analysis of 36 Cases. World Neurosurg. 2022. PMID: 36332774. doi:10.1016/j.wneu.2022.10.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。